Cutaneous T-cell Lymphoma

P2, N=35, Not yet recruiting, Peking University First Hospital

After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.

The finding of this cohort study suggest that adult HMF demonstrated a generally indolent course, with favorable response to skin-directed therapy, irrespective of immunophenotype or mixed-variant presentation. Peripheral blood TCR monoclonality was associated with lower treatment response but not disease progression.

P1, N=45, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 45 | Trial completion date: May 2040 --> Mar 2041

Given the lesion's location in a cosmetically sensitive area, care was coordinated with dermatology, hematology/oncology, and plastic surgery. This case highlights the importance of clinicopathologic correlation in distinguishing PCSM-TCLPD from its malignant mimickers and in guiding appropriate management.

P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78

P1, N=10, Suspended, University of Alabama at Birmingham | Trial completion date: Jul 2026 --> Jul 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Jun 2027

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed

BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.

Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod...In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via dendritic cells and enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma.